Photothermal Targetting therapy of A20 Mouse Lymphoma model using Anti CD-138 Antibody conjugated Gold Nanospheres

Yang, Lin; Meng, Hu; Zong, Yunhui; Qian, Jianfei; Yu, Jing; Tang, Jessica; Zou, Jianxuan; An, Gangli; Song, Ha Yong; Zhang, Xingding

doi:10.4172/2329-8790.1000137

Cited by 1 publication

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that anti-CD138-Ab exhibited more selectively toward A20 cells than R-Ab, and the tunable band for hollow AuNPs was 520-950 nm. These findings indicated that anti-CD138-Ab-PEG-AuNPs could be used for PTT-based lymphoma treatment[96].…”

mentioning

confidence: 80%

“…It should be noted that the anti-CD33 antibody already got approval for AML treatment [95]; therefore, CD33-Ab-PEG-GNR could be used to treat AML. [96] loaded anti-CD138 antibody (anti-CD138-Ab) on the surface of PEG-modified hollow AuNPs (anti-CD138-Ab-PEG-AuNPs) that selectively target A20 lymphoma cells. Treatment of female BALB/c mice with anti-CD138-Ab-PEG-AuNPs followed by NIR treatment (after 24 h) significantly decreased lymphoma growth and IgG2a expression at 4 days compared to a control.…”

Section: Photothermal Therapymentioning

confidence: 99%

“…Photothermal therapy: PTT; Photodynamic therapy: PDT; Gold nanomaterials: GNM; Near-infrared radiation: NIR; Antibody: Ab; Aptamer: Apt; Reactive oxygen species: ROS. Yang et al (2014)[96] loaded anti-CD138 antibody (anti-CD138-Ab) on the surface of PEG-modified hollow AuNPs (anti-CD138-Ab-PEG-AuNPs) that selectively target A20 lymphoma cells. Treatment of female BALB/c mice with anti-CD138-Ab-PEG-AuNPs followed by NIR treatment (after 24 h) significantly decreased lymphoma growth and IgG2a expression at 4 days compared to a control.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies

Shakil

Niloy

Mahmud

et al. 2022

Cancers

View full text Add to dashboard Cite

Hematological malignancies (HMs) are a heterogeneous group of blood neoplasia generally characterized by abnormal blood-cell production. Detection of HMs-specific molecular biomarkers (e.g., surface antigens, nucleic acid, and proteomic biomarkers) is crucial in determining clinical states and monitoring disease progression. Early diagnosis of HMs, followed by an effective treatment, can remarkably extend overall survival of patients. However, traditional and advanced HMs’ diagnostic strategies still lack selectivity and sensitivity. More importantly, commercially available chemotherapeutic drugs are losing their efficacy due to adverse effects, and many patients develop resistance against these drugs. To overcome these limitations, the development of novel potent and reliable theranostic agents is urgently needed to diagnose and combat HMs at an early stage. Recently, gold nanomaterials (GNMs) have shown promise in the diagnosis and treatment of HMs. Magnetic resonance and the surface-plasmon-resonance properties of GNMs have made them a suitable candidate in the diagnosis of HMs via magnetic-resonance imaging and colorimetric or electrochemical sensing of cancer-specific biomarkers. Furthermore, GNMs-based photodynamic therapy, photothermal therapy, radiation therapy, and targeted drug delivery enhanced the selectivity and efficacy of anticancer drugs or drug candidates. Therefore, surface-tuned GNMs could be used as sensitive, reliable, and accurate early HMs, metastatic HMs, and MRD-detection tools, as well as selective, potent anticancer agents. However, GNMs may induce endothelial leakage to exacerbate cancer metastasis. Studies using clinical patient samples, patient-derived HMs models, or healthy-animal models could give a precise idea about their theranostic potential as well as biocompatibility. The present review will investigate the theranostic potential of vectorized GNMs in HMs and future challenges before clinical theranostic applications in HMs.

show abstract

mentioning

confidence: 80%

Section: Photothermal Therapymentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation